TSPO-PET for Neuroinflammation in Parkinson's Disease
The primary objective of this substudy is to measure the concentration and the regional brain distribution of activated brain microglia/macrophages using the PET ligand [18F]DPA-714 in participants enrolled in the UAB Neuroinflammation in PD study. The PET tracer [18F]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia/macrophages and provides a non-invasive measure of neuroinflammation. The amount and distribution of [18F]DPA-714 in the brain will be correlated to clinical data acquired through the separate ongoing Neuroinflammation in PD study. The primary objective of this study is to determine if patients with PD have higher levels of neuroinflammation than healthy controls as measured with [18F]DPA-714-PET/MRI.
- Parkinson Disease
- Eligible Ages
- Over 30 Years
- Eligible Genders
- Accepts Healthy Volunteers
- Enrollment in the UAB Neuroinflammation in PD study under the separate UAB approved research protocol IRB-300000690.
- Negative urine or serum hCG test within 2 days of [18F]DPA-714-PET administration in women of child bearing potential. Women who are post-menopausal with at least 1 year since last menses or documented surgical sterilization will not require pregnancy testing.
- High or mixed affinity binder for TSPO ligands based on genotyping for single nucleotide polymorphism (SNP) rs6971.
- Meets any exclusion criteria for the UAB Neuroinflammation in PD study.
- Contraindication to MRI and/or PET imaging
- Inability to participate in the imaging studies due to severity of PD or other medical comorbidities.
- Low affinity binder for TSPO ligands based on genotyping for SNP rs6971. -
- Phase 1/Phase 2
- Study Type
- Intervention Model
- Single Group Assignment
- Primary Purpose
- None (Open Label)
Healthy Controls, DPA-714-PET/MRI
Early Parkinson's Disease, DPA-714-PET/MRI
- University of Alabama at Birmingham
Study ContactJonathan McConathy, MD